Skip to main content

Month: January 2024

Helium-3 Market Size Worth USD 888.6 Million in 2032 | Emergen Research

Rising demand for detecting equipment and increasing adoption of Magnetic Resonance Imaging (MRI) and other medical imaging modalities are key factors driving helium-3 market revenue growth. Vancouver, Jan. 10, 2024 (GLOBE NEWSWIRE) — The global helium-3 market size was USD 378.0 Million in 2022 and is expected to register a rapid revenue CAGR of 9.0% during the forecast period. Rising demand for detecting equipment and increasing adoption of Magnetic Resonance Imaging (MRI) and other medical imaging modalities are key factors driving market revenue growth.   The global demand for detection equipment is rising rapidly due to increasing popularity of fast neutron spectroscopy measurements, with the demand for helium-3 reaching 65,000litres per year. Most of this demand will be driven by helium detectors used in medical labs, particularly...

Continue reading

Herbal Supplements Market Size Worth USD 172.99 Billion in 2032 | Emergen Research

Increasing disposable income of working population and rising consumer interest in natural and holistic health remedies are key factors driving Herbal Supplements markets revenue growth. Vancouver, Jan. 10, 2024 (GLOBE NEWSWIRE) — The global herbal supplements market size was USD 86.84 billion in 2022 and is expected to register a rapid revenue CAGR of 7.3% during the forecast period. Increasing disposable income of working population and rising consumer interest in natural and holistic health remedies are key factors driving markets revenue growth. The rising costs for pharmaceutical and nutritional goods and adverse effects of allopathic medications are other key factors driving revenue growth of the market. Increasing number of health-conscious consumers who are interested in enhancing their well-being are drawn to herbal supplements...

Continue reading

Dry Eye Syndrome Market Size Worth USD 10.55 Billion in 2032 | Emergen Research

Rising demand for effective treatments, and strong R&D investments to support pipeline candidates are expected to drive Dry Eye Syndrome market growth. Vancouver, Jan. 10, 2024 (GLOBE NEWSWIRE) — The global dry eye syndrome market size was USD 5.32 billion in 2022 and is expected to register a revenue CAGR of 7.3% during the forecast period. Increasing cases of dry eye syndrome across the globe, widespread use of digital devices, such as computers, smartphones, and tablets, numerous Research & Development (R&D) activities by market players, rising demand for effective treatments, and strong R&D investments to support pipeline candidates are expected to drive market revenue growth. One of the major factors driving revenue growth of the market is increasing number of dry eye syndrome cases due to the excess utilization...

Continue reading

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months Results demonstrated a 61% increase in preventative drug prescriptions among patients in the high-risk group and improved specialist referrals which can significantly reduce overall cost of care and improve patient outcomes LONDON and SALT LAKE CITY, Jan. 10, 2024 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces publication of Real World Evidence (“RWE”) after 12 months of follow-up in 2,569 patients with Type 2 diabetes and diabetic kidney disease (“DKD”) at a major U.S. health system in Primary Care and Community Health. Results in the diverse cohort, including 27% black patients, demonstrate that electronic health...

Continue reading

OTC Markets Group Welcomes Argentina Lithium & Energy Corp to OTCQX

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Argentina Lithium & Energy Corp (TSX-V: LIT; OTCQX: LILIF), an alternative fuel material company, has qualified to trade on the OTCQX® Best Market. Argentina Lithium & Energy Corp upgraded to OTCQX from the OTCQB® Venture Market. Argentina Lithium & Energy Corp begins trading today on OTCQX under the symbol “LILIF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance,...

Continue reading

Mayfair Gold Drills 3.14 g/t Au over 10.0m including 15.94 g/t Au over 1.0m at Fenn-Gib Footwall Zone

Hole FG23-359 reports 27.60 g/t Au over 2.1m, hole FG23-361 intersected 16.47 g/t Au over 2.3m and hole FG23-351 reported 2.19 g/t Au over 16.8m, including 3.28 g/t Au over 7.0 and 3.21 g/t Au over 2.0m Mineralization outside current Fenn-Gib pit-constrained 3.38M ounce deposit Footwall Zone structure over 500m strike length, open in all directions Steep dipping mineralization from surface to below 600m Multiple parallel mineralized structures intersected Two drill rigs active at Footwall ZoneVANCOUVER, British Columbia, Jan. 10, 2024 (GLOBE NEWSWIRE) — Mayfair Gold Corp. (“Mayfair” or the “Company”) (TSX-V: MFG; OTCQB: MFGCF) is pleased to announce further results from the higher-grade Footwall Zone located approximately 100 meters (m) to the northwest of the Fenn-Gib gold deposit. Mayfair’s 100% controlled Fenn-Gib Project,...

Continue reading

Arqit announces reseller agreement with Phalanx

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, today announced a reseller agreement with Phalanx Solutions (Phalanx), a trusted provider of security, compliance and technology solutions, for Arqit’s Symmetric Key Agreement Platform and NetworkSecure™ Adaptor. Enterprises face growing threats from cyber adversaries and need to take urgent action to strengthen their encryption in the ever-connected world of devices. Easily integrated at modest cost with dynamic rotating authentication, Arqit’s Platform as a Service makes symmetric encryption keys which cannot be broken even by quantum attack. Arqit’s standards-compliant technology is now available to Phalanx’s clients as a deployable solution. Phalanx Solutions is a leading provider of comprehensive...

Continue reading

Climb Channel Solutions Announces Expanded Partnership with Jamf to Offer Apple Device Management and Protection to US Reseller Partners

EATONTOWN, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) has expanded their partnership with Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, to their US offerings. The partnership between Jamf and Climb Channel Solutions holds immense value in the realm of technology and business solutions. Jamf, a leading provider of Apple device management and security software, and Climb Channel Solutions, a renowned distributor of innovative technology products, bring together their expertise and resources to deliver exceptional solutions to organizations. This partnership, which has already seen success in Canada, empowers businesses to efficiently manage and secure their Apple...

Continue reading

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

WATERTOWN, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase 2 VERONA clinical trial of EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E. “Dosing the first patient in the Phase 2 VERONA trial represents another significant milestone in advancing our mission to improve the lives of patients with serious retinal diseases. DME is a common sight-threatening complication of diabetes that can lead to severe vision loss. It represents the second diabetic eye...

Continue reading

HBT Financial, Inc. to Announce Fourth Quarter 2024 Financial Results on January 24, 2024

BLOOMINGTON, Ill., Jan. 10, 2024 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT”), the holding company for Heartland Bank and Trust Company, today announced that it will issue its fourth quarter 2024 financial results before the market opens on Wednesday, January 24, 2024. A copy of the press release announcing the fourth quarter 2024 financial results and an investor presentation will be made available on the Company’s investor relations website at https://ir.hbtfinancial.com. About HBT Financial, Inc. HBT Financial, Inc., headquartered in Bloomington, Illinois, is the holding company for Heartland Bank and Trust Company, and has banking roots that can be traced back to 1920. HBT provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.